A service evaluation of the prescribing pharmacist led isotretinoin clinic and it’s adherence to MHRA prescribing requirements for isotretinoin
Loading...
Authors
Wansongi, Magalie
Alabi, Oluseyi
Jalal, Helin
Hassan, Ibrahim
Herath, Dimalee
Contact
Check for full-text access
Issue Date
2025
Type
Presentation
Language
Keywords
Alternative Title
Abstract
Post covid pandemic, there was an increased pressure on consultants due to the backlog of unseen patients, thus an increased waiting list. This led for the need of an additional clinic (The prescribing pharmacist led isotretinoin clinic) to alleviate pressure and decrease the current waiting list. The prescribing pharmacist will see the patient at their second appointment and continue the patients treatment (this includes starting treatment, reviewing, monitoring, prescribing and treatment cessation), liaising with the consultant should there be any interventions needed
Isotretinoin is a retinoid drug licensed for the treatment of severe acne or acne resistant to standard therapy (systemic antibacterial and topical therapy). Due to its safety profile and associated risks 1, 2,3 the Medicines and Healthcare products Regulatory Agency (MHRA) have issued new requirements for their prescribing1,2,3. These requirements, which came into effect in January 2024, has led to a review of the pharmacist prescribing service provided at Croydon University Hospital (CUH).
Description
Audit poster winner 2025
Citation
Publisher
Croydon Health Services NHS Trust